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Retrospective community based explorative study on Cisplatin-based adjuvant chemotherapy 
vs. surgery only in completely resected stage IB non-small cell lung cancer (NSCLC). 
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2, Jens Benn Sørensen, MD, DMSc¹ 
¹Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark.  
2Dept. Of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark 
Background 
The benefit of adjuvant chemotherapy (ACT) following 
complete surgery in NSCLC stage IB is not fully clarified. 
ACT in this situation is currently considered optional 
(ESMO guidelines). 
 
Aim 
• Examine a consecutive group of unselected 
completely resected NSCLC stage IB patients who 
either received adjuvant chemotherapy or surgical 
resection only 
• compare overall survival (OS) and disease free 
survival (DFS) between the two groups 
Methods 
• Patients underwent complete radical surgery, 2005-
2012  
• All patients were considered fit for ACT with cisplatin 
and vinorelbine were offered adjuvant tretment.  
• Some pts decided to receive ACT creating the 
proband group (PG) 
• Other patients declined being the control group (CG)  
• 63 variables were collected from medical and surgical 
records.  
• Co-morbidity was scored according to Charlson’s co-
morbidity score (CCMS).  
• OS and DFS were calculated using Kaplan-Meier plots 
A multivariate Cox regression analysis was performed 
to explore on predictors for outcome. 
Results 
• Totally 184 pts were reviewed, 
patient characteristics presented 
in table 1. 
•  The patients in the CG were older 
(p<0.001), had higher CCMS 
(p<0.001), and had more pts with 
pleural invasion (p=0.028) than 
the PG group.  
•  OS: 5-year OS was 80 % for PG vs. 
59 % in CG, p: 0.03 
•  DFS: 5-year DFS in PG was 73 % 
and 54 % in CG, p=0.024. 
•  The Cox regression analysis, table 
2 revealed that ACT (p=0.02), low 
CCS (p=0.003) and low 
performance status (p=0.035) 
were independent significant 
prognostic factors regarding 
better OS. 
 
Conclusions 
Patients who decided to receive ACT 
were younger and had lower CCS. 
ACT was an independent prognostic 
factor and patients receiving ACT 
benefitted significantly with respect 
to both DFS and OS when compared 
to controls without ACT. 
 
Table 1. Patient characteristics 
  Proband group Control group p-value 
  n= 74 (%) n= 110 (%)   
Age (median, (range)) 64 (40-78) 68 (44-81) <0.001 
        
Gender       
-female 45 (60) 63 (57) 0.65 
-male 29 (40) 47 (43) 0.63 
        
Performance status     0.13 
0 31 (42) 53 (48)   
1 18 (24) 49 (45)   
2   2 (2)   
NA 25 (34) 6 (5)   
        
Smoking status     0.67 
-Active smoker 50 (68) 77 (70)   
-Earlier smoker (quit >1 year ago) 19 (25) 28 (25)   
-Never smoker 5 (7) 5 (5)   
        
Histologi     0.62 
-adenocarcinoma 52 (70) 74 (67)   
-squamous cell carcinoma 16 (22) 23 (21)   
-other 6 (8) 13 (12)   
        
Tumorsize, mm  (median, (range)) 33 (7-90) 32 (8-90) 0.25 
        
Charlson's Comorbidity Score     <0.001 
Low (0-2) 30 (41) 23 (21)   
Moderate (3-5) 35 (47) 77 (70)   
High > 5 1 (1) 10 (9)   
NA 8 (11)     
        
Pleural invasion     0.028 
No pleural involvement 23 (31) 18 (16)   
Pleural involvement 47 (64) 87 (79)   
Tumorgrowth through the pleura 3 (4) 5 (5)   
NA 1 (1)     
Table 2. Factors influencing OS and DFS in a multivariate setting 
Overall survival, 5-year      
Variable p-value HR (95 % CI) 
ACT 0.02 0.33 (0.13-0.84) 
CCM score 0.003 1.31 (1.09-1.56) 
Perfomance status 0.035 1.92 (1.05-3.52) 
      
Disease free survival, 5-year     
Variable p-value HR (95 % CI) 
ACT 0.026 0.49 (0.26-0.92) 
CCM score 0.007 1.23 (1.06-1.43) 
Method used: cox proportional hazard  
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